Sickle Cell Disease

Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by a mutation in the HBB gene on chromosome 11. This gene provides instructions for making beta-globin, one of the two protein subunits that form hemoglobin, the oxygen-carrying molecule inside red blood cells. When a person inherits two copies of the sickle hemoglobin gene (one from each parent), their red blood cells produce an abnormal form of hemoglobin called hemoglobin S (HbS). Under low-oxygen conditions, HbS molecules stick together and form long, rigid chains that distort the normally round, flexible red blood cell into a crescent or "sickle" shape.

These sickle-shaped cells are stiff and sticky. They tend to clump together and get stuck in small blood vessels, blocking the flow of blood and oxygen to tissues throughout the body. This process, called vaso-occlusion, is the root cause of most SCD complications, including severe pain episodes, organ damage, and stroke. Sickle cells also break apart much faster than normal red blood cells. While healthy red blood cells live about 120 days, sickle cells survive only 10 to 20 days, leading to a constant shortage of red blood cells known as chronic hemolytic anemia.

SCD affects approximately 100,000 people in the United States and millions worldwide. It is most common among people whose ancestors come from sub-Saharan Africa, South America, the Caribbean, Central America, Saudi Arabia, India, and Mediterranean countries such as Turkey, Greece, and Italy. In the United States, SCD occurs in about 1 in every 365 Black or African American births and about 1 in every 16,300 Hispanic American births. The sickle cell trait (carrying one copy of the HbS gene) is far more common, affecting about 1 in 13 Black or African American babies.

SCD is typically diagnosed through newborn screening, which has been mandatory in all 50 U.S. states since 2006. A simple blood test called hemoglobin electrophoresis can identify the type and amount of hemoglobin present. There are several forms of SCD, with hemoglobin SS (HbSS) being the most common and generally most severe. Other forms include hemoglobin SC (HbSC), hemoglobin S beta-plus thalassemia (HbS beta+), and hemoglobin S beta-zero thalassemia (HbS beta0). The specific type a person has affects the severity and pattern of symptoms they experience.

The natural history of SCD varies widely. Some individuals experience frequent, debilitating pain crises and serious complications from early childhood, while others have a milder disease course. Over time, repeated episodes of vaso-occlusion and chronic anemia cause cumulative damage to virtually every organ system, including the spleen, kidneys, lungs, brain, bones, and eyes. Life expectancy for people with SCD has improved significantly with modern medical care, from a median of 14 years in 1973 to approximately 54 years for women and 50 years for men today, though substantial gaps remain compared to the general population.

The most well-known symptom of SCD is the pain crisis, also called a vaso-occlusive crisis (VOC). These episodes occur when sickle-shaped red blood cells block blood flow through small blood vessels, cutting off oxygen to surrounding tissues. Pain crises can happen anywhere in the body but most commonly affect the chest, abdomen, lower back, arms, legs, and joints. The pain is often described as deep, throbbing, and severe. A crisis can last from a few hours to several weeks, and the frequency varies greatly between individuals, from none in a given year to more than a dozen.

Chronic anemia is a constant companion for most people with SCD. Because sickle cells break down so quickly, the body cannot make new red blood cells fast enough to keep up. This chronic shortage of red blood cells causes ongoing fatigue, weakness, dizziness, shortness of breath, and pale skin or yellowish eyes (jaundice). Children with SCD may grow more slowly than their peers and reach puberty later. The anemia can worsen suddenly during an aplastic crisis, usually triggered by parvovirus B19 infection, when the bone marrow temporarily stops producing red blood cells.

SCD affects multiple organ systems over time. In the spleen, repeated damage from sickle cells leads to functional asplenia (loss of spleen function) by early childhood in most HbSS patients, increasing vulnerability to life-threatening bacterial infections from organisms like Streptococcus pneumoniae and Haemophilus influenzae. In the lungs, acute chest syndrome, a condition involving chest pain, fever, and a new lung infiltrate on X-ray, is the leading cause of death and the second most common reason for hospitalization. In the brain, silent cerebral infarcts affect up to 39% of children with HbSS by age 18, and overt stroke occurs in about 11% without preventive treatment.

Additional complications include avascular necrosis (bone death) in the hips and shoulders, proliferative retinopathy that can lead to vision loss, chronic kidney disease progressing to kidney failure, leg ulcers that are slow to heal, priapism (prolonged, painful erections) in males, and gallstones from chronic red blood cell breakdown. Pulmonary hypertension, an elevation of blood pressure in the lung arteries, develops in approximately 6-10% of adults with SCD and is associated with increased mortality.

Daily management centers on prevention and healthy habits. Staying well-hydrated is one of the most important strategies, as dehydration concentrates the blood and promotes sickling. Most specialists recommend drinking 8 to 10 glasses of water daily, with more during exercise, hot weather, or illness. Avoiding temperature extremes is equally important: cold exposure causes blood vessels to constrict, increasing the risk of vaso-occlusion, while overheating leads to dehydration and increased oxygen demand.

Regular medical monitoring is essential for managing SCD effectively. This includes complete blood counts every 3 to 6 months, annual transcranial Doppler ultrasound for children aged 2 to 16 to screen for stroke risk, annual eye examinations starting by age 10, kidney function tests, echocardiograms to monitor for pulmonary hypertension, and assessment of iron overload in patients receiving chronic transfusions. Keeping an up-to-date health maintenance schedule and a personal symptom diary can help patients and their care teams identify patterns and intervene early.

Hydroxyurea (brand name Droxia, Hydrea, Siklos) remains the most widely prescribed disease-modifying therapy for SCD. Approved by the FDA for adults with SCD in 1998 and for children aged 2 and older in 2017, hydroxyurea works primarily by increasing the production of fetal hemoglobin (HbF), a form of hemoglobin that does not participate in the sickling process. Higher HbF levels dilute the concentration of HbS within each red blood cell, reducing the likelihood of sickling. Clinical studies have shown that hydroxyurea reduces the frequency of pain crises by approximately 50%, decreases the need for blood transfusions and hospitalizations, lowers the risk of acute chest syndrome, and may improve overall survival. Despite its proven benefits, hydroxyurea remains underutilized, with estimates suggesting that only 25-30% of eligible patients in the United States are receiving it.

Three additional FDA-approved medications target different aspects of SCD pathophysiology. Endari (L-glutamine oral powder), approved in 2017, is an amino acid supplement that helps protect red blood cells from oxidative damage, reducing the frequency of pain crises and hospitalizations. Adakveo (crizanlizumab-tmca), approved in 2019, is a monoclonal antibody administered by intravenous infusion every four weeks that blocks P-selectin, a protein involved in the adhesion of sickle cells to blood vessel walls, thereby reducing vaso-occlusion. Oxbryta (voxelotor), approved in 2019, works by directly binding to hemoglobin S and preventing the polymerization that causes red blood cells to sickle, which increases hemoglobin levels and reduces markers of red blood cell destruction.

In December 2023, the FDA approved two gene therapies for SCD, marking a historic advance. Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, became the first CRISPR-based gene therapy approved for any disease. It works by editing the BCL11A gene in the patient's own stem cells, reactivating fetal hemoglobin production. Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio, uses a lentiviral vector to add a modified beta-globin gene (called HbAT87Q) that produces an anti-sickling form of hemoglobin. Both therapies require myeloablative conditioning (chemotherapy to make room in the bone marrow) before infusion of the modified stem cells, followed by a period of immune recovery.

Blood transfusions remain a cornerstone of SCD management for both acute and chronic indications. Simple transfusions increase the total hemoglobin level, while exchange transfusions (also called red cell exchange or erythrocytapheresis) replace sickle cells with donor red blood cells, reducing the HbS percentage while avoiding volume overload. Chronic transfusion therapy, typically administered every 3 to 4 weeks, is used for primary stroke prevention in children with abnormal transcranial Doppler results and for secondary stroke prevention after a first stroke. The main risks of chronic transfusion include alloimmunization (developing antibodies against donor red blood cell antigens, which occurs in up to 30% of SCD patients), iron overload requiring chelation therapy, and transfusion reactions.

Bone marrow (hematopoietic stem cell) transplant from a matched sibling donor remains the only widely established cure for SCD outside of gene therapy. When performed in childhood using a matched sibling donor, cure rates exceed 90%. However, fewer than 20% of patients have a fully matched sibling, and transplants from alternative donors (haploidentical family members or unrelated donors) carry higher risks of graft failure and graft-versus-host disease. Ongoing research is working to expand donor options and improve the safety of transplant for adults and those without matched siblings.

The clinical trial pipeline for SCD is more active than at any point in history. As of early 2026, there are over 100 active clinical trials studying new treatments, ranging from next-generation gene therapies to novel small molecules targeting different aspects of the disease. This expansion follows decades during which SCD research was underfunded relative to its prevalence and severity, a disparity increasingly recognized and addressed by funding agencies, pharmaceutical companies, and advocacy organizations.

Gene therapy and gene editing trials represent some of the most closely watched programs. Beyond the two approved gene therapies, several next-generation approaches are in clinical development. These include in-vivo gene editing strategies that would deliver CRISPR components directly into the body without the need to extract and modify stem cells outside the body, potentially making the treatment less intensive and more accessible. Base editing approaches, which make precise single-letter changes to DNA without cutting both strands, are being explored as potentially safer alternatives to traditional CRISPR editing.

Small molecule therapies in clinical trials are targeting multiple pathways involved in SCD. Fetal hemoglobin inducers beyond hydroxyurea, including several oral agents, aim to achieve higher and more consistent HbF elevation. Anti-adhesion molecules target different adhesion receptors to prevent sickle cells from sticking to blood vessel walls. Anti-inflammatory agents address the chronic inflammatory state that contributes to vaso-occlusion and organ damage. Pyruvate kinase activators, which have shown benefit in other hemolytic anemias, are being studied for their ability to improve red blood cell metabolism and reduce sickling.

Participating in a clinical trial is a personal decision that requires careful consideration. Patients interested in trials should discuss their options with their hematologist and consider factors including their current treatment regimen, disease severity, the trial's location and time commitment, and the potential risks and benefits of the experimental therapy. ClinicalTrials.gov is the primary registry for finding active studies, and organizations like the Sickle Cell Disease Association of America (SCDAA) maintain resources to help patients understand and navigate the trial landscape. Basion monitors the global trial registry and can match you with trials based on your specific genotype, treatment history, and location.

Access to SCD treatments presents significant challenges, particularly for newer therapies. The two approved gene therapies, Casgevy and Lyfgenia, are priced at approximately $2.2 million and $3.1 million per treatment, respectively, making them among the most expensive medical treatments ever. While these are intended as one-time treatments with the potential for long-term disease modification, the upfront cost creates substantial barriers. Most patients with SCD in the United States are covered by Medicaid, which varies by state in its coverage policies for gene therapies. Medicare and private insurers are developing coverage criteria as well, but the process is evolving.

Prior authorization is required for nearly all SCD-specific medications and is especially extensive for gene therapies. For gene therapy coverage, insurers typically require documentation of a confirmed SCD diagnosis (including genotype), evidence of disease severity such as the frequency of pain crises and hospitalizations, documentation that the patient has tried and responded inadequately to standard therapies like hydroxyurea, and evaluation at an authorized treatment center. The prior authorization and appeals process can take months, during which patients may experience disease complications that could have been prevented or treated.

Financial assistance programs exist to help offset the cost of SCD treatments. Manufacturers of SCD medications often offer patient assistance programs, copay assistance cards, and free drug programs for uninsured or underinsured patients. Organizations like the Patient Advocate Foundation and the HealthWell Foundation provide grants and case management services. State pharmaceutical assistance programs may also help with medication costs. It is worth asking your treatment center's social worker about all available resources, as navigating these programs can be time-consuming but can substantially reduce out-of-pocket expenses.

Basion helps patients navigate insurance by automatically compiling medical records, generating evidence summaries for prior authorization, and providing templates for appeal letters when coverage is denied. For patients considering gene therapy, Basion can help identify authorized treatment centers, understand the evaluation process, and coordinate the documentation needed for coverage determination. Understanding your rights under your insurance plan, including the external review process mandated by the Affordable Care Act, is an important part of advocating for access to the treatments you and your doctor believe are appropriate.

Hematologists with expertise in sickle cell disease are the primary specialists for ongoing SCD care. However, many patients also benefit from a multidisciplinary care team that includes pain management specialists, pulmonologists (for acute chest syndrome and pulmonary hypertension), nephrologists (for kidney complications), ophthalmologists (for retinopathy screening), orthopedic surgeons (for avascular necrosis), psychologists or psychiatrists (for the mental health impact of chronic illness), and social workers (for care coordination and resource navigation). The complexity of SCD means that no single specialist can address all aspects of the disease.

Comprehensive Sickle Cell Centers, many of which are affiliated with academic medical centers, offer coordinated multidisciplinary care. These centers typically follow evidence-based guidelines published by the National Heart, Lung, and Blood Institute (NHLBI) and the American Society of Hematology (ASH). The NHLBI maintains information on sickle cell centers, and the ASH provides a directory of hematologists with SCD expertise. Major comprehensive centers include those at Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, Emory University, NIH Clinical Center, Columbia University, and the University of Alabama at Birmingham, among others.

Transitioning from pediatric to adult care is one of the most critical and challenging periods for people with SCD. Pediatric sickle cell programs typically provide highly coordinated, family-centered care with strong social support. Adult programs may be less comprehensive, and many adult hematologists have limited experience with SCD compared to other blood disorders. The transition period, usually between ages 18 and 25, is associated with increased emergency department visits, hospitalizations, and even mortality. Starting the transition process early, ideally by age 12 to 14, and working with both pediatric and adult teams to ensure a gradual handoff of care responsibilities can help prevent gaps in treatment. Basion helps identify adult hematologists experienced in SCD and facilitates the transfer of medical records between care teams.

Living with SCD can be isolating, but a growing community of patients, caregivers, and advocates is working to change that. The Sickle Cell Disease Association of America (SCDAA) is the oldest and largest national organization dedicated to SCD, providing support, education, advocacy, and programming at the national and chapter levels. SCDAA chapters organize local support groups, educational events, summer camps for children with SCD, and advocacy campaigns to increase funding and awareness. Their annual convention brings together patients, families, researchers, and healthcare providers.

Several other organizations provide important resources. The Sickle Cell Foundation (various regional chapters), the National Alliance of Sickle Cell Centers, and Sick Cells are prominent advocacy organizations. Global Blood Therapeutics (now part of Pfizer) and other pharmaceutical companies sponsor patient education programs and support communities. The American Society of Hematology's SCD Initiative works to improve care quality and access. For children, organizations like Camp Horizon and similar programs offer recreational experiences designed specifically for youth with SCD.

Online communities have become increasingly important for SCD support. Social media groups on platforms like Facebook and Reddit connect patients and caregivers across geographic boundaries, allowing people to share experiences, coping strategies, and information about treatments and trials. Peer mentorship programs, where experienced patients guide those who are newly diagnosed or going through transitions like starting a new treatment or managing pregnancy with SCD, provide particularly valuable support. Basion connects you with disease-specific communities and can help you find local support groups, events, and advocacy opportunities near you.

Caregivers of people with SCD face a unique set of challenges that evolve as the patient ages. Parents of young children must learn to recognize the early signs of potentially life-threatening complications, manage daily medications and preventive care, coordinate frequent medical appointments, and advocate for their child in school and healthcare settings. As children grow into adolescents and young adults, caregivers shift from direct management to supporting increasing independence while remaining vigilant for complications that may require urgent intervention.

Understanding emergency warning signs is essential for every SCD caregiver. Seek immediate medical attention for: fever above 101 degrees F (38.3 degrees C), as infection can be rapidly fatal in people with SCD who have lost spleen function; severe pain that does not respond to prescribed home pain medications within 1 to 2 hours; sudden weakness or numbness on one side of the body, difficulty speaking, or sudden severe headache, which may indicate stroke; difficulty breathing, chest pain, or rapid heart rate, which may signal acute chest syndrome; sudden increase in pallor or jaundice, abdominal pain with swelling, or unusual fatigue, which may suggest splenic sequestration (in young children) or aplastic crisis.

School and workplace accommodations are important for people with SCD. Children may need accommodations such as unlimited bathroom access (due to the kidney's inability to concentrate urine), access to water throughout the day, modified physical education during extreme weather, extra time for assignments during and after pain crises, and homebound instruction during extended absences. Adults may benefit from workplace accommodations under the Americans with Disabilities Act, including flexible scheduling, access to temperature-controlled environments, and modified physical demands. Documentation from the treating hematologist can support formal accommodation requests.

Caregiver wellbeing deserves attention and investment. The chronic nature of SCD, the unpredictability of pain crises, the emotional toll of watching a loved one suffer, and the financial burden of frequent medical care can lead to caregiver burnout, depression, and anxiety. Studies show that caregivers of children with SCD report higher rates of psychological distress than caregivers of children with other chronic conditions. Seeking support through counseling, caregiver support groups (many SCDAA chapters offer these), and respite care programs can help maintain long-term wellbeing. It is not selfish to prioritize your own health; it is necessary for sustaining the care your loved one needs.

The research pipeline for SCD is robust and expanding across multiple therapeutic approaches. In-vivo gene editing, which would deliver gene-editing tools directly into the body to modify stem cells without the need for extraction, conditioning chemotherapy, and reinfusion, is a major area of investigation. If successful, this approach could make curative gene therapy far more accessible by eliminating the need for specialized transplant centers and reducing the overall treatment burden. Several academic and industry groups are working on lipid nanoparticle and AAV-based delivery systems to achieve efficient in-vivo editing of hematopoietic stem cells.

Beyond gene therapy, a rich pipeline of novel therapeutics is in preclinical and clinical development. Next-generation fetal hemoglobin inducers aim to achieve higher HbF levels than hydroxyurea alone, with several oral agents showing promising results in early trials. Anti-polymerization agents target the molecular process by which HbS forms rigid polymers inside red blood cells. Complement pathway inhibitors address the inflammatory cascade triggered by chronic hemolysis. And novel anti-adhesion molecules target additional cell surface receptors beyond P-selectin to prevent vaso-occlusion more completely.

Real-world evidence studies are increasingly important for understanding long-term outcomes. As gene therapies and newer medications enter clinical use, tracking patient outcomes over years and decades is essential for understanding durability, long-term safety, and quality of life impact. Patient registries, including the Sickle Cell Data Collection Program supported by the CDC and the GRNDaD registry maintained by the ASH Research Collaborative, are collecting longitudinal data that will inform treatment decisions and healthcare policy for years to come. Basion contributes to this ecosystem by helping patients share their outcomes data (with consent) to accelerate research and improve understanding of treatment effectiveness across diverse populations.

This information is provided for educational purposes and does not replace professional medical advice. Always consult your healthcare provider before making decisions about your treatment. Medical information in this guide reflects the state of knowledge as of February 2026.